Effects of Different Doses of Esketamine on Postoperative Analgesia and Recovery Quality in Lumbar Decompression Surgery: A Randomized Controlled Trial Focusing on the Advantages of Sub-Anesthetic Doses

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background : The optimal esketamine dose for opioid-sparing analgesia in lumbar decompression surgery remains controversial, particularly regarding its dose-dependent effects on recovery quality and safety. Methods : In this single-center, parallel-group, assessor-blinded randomized controlled trial, 120 patients were allocated via computer-generated randomization (1:1:1:1) to four groups:Group N: Sufentanil2.5µg/kg (control);Groups S1–S3: Esketamine 0.25/0.5/1.0 mg/kg + sufentanil 1.5µg/kg.Primary outcomes included postoperative analgesic consumption, rescue analgesia requirements, and 12-hour VAS scores. Secondary outcomes comprised stress markers and adverse events. Results : No significant differences were observed in rescue analgesia frequency among groups (P > 0.05). However, Group S1 (0.25 mg/kg esketamine) demonstrated significantly lower VAS scores versus Group N (mean difference − 1.8, 95% CI − 2.1 to − 1.5; P < 0.001) and a lower incidence of psychiatric symptoms than Group S3 (6.67% vs. 20.0%; RR 0.33, P = 0.032). Stress markers showed no dose-dependent trends (P > 0.05). While overall adverse event rates were comparable (P > 0.05), high-dose esketamine (S3) was associated with increased hypotension and dissociative symptoms (P < 0.05). Conclusions : Esketamine 0.25 mg/kg effectively reduces sufentanil consumption, prolongs analgesia, and achieves an optimal balance between efficacy and safety in lumbar decompression surgery. Trial registration: ChiCTR-2500095890, 15 January 2025.

Article activity feed